Supplementary Figure 2: Gating strategy to identify stem and progenitor subpopulations within the CD34+ cells.
From: CRISPR/Cas9 genome editing in human hematopoietic stem cells
Representative FACS plots are shown from the analysis of CD34+ cells freshly isolated from cord blood. Cells were stained for human lineage markers (CD2, CD3, CD4, CD8, CD16, CD19, CD20, CD56, CD235a, and CD14), as well as CD34, CD38, CD90, CD45RA, and CD123. The gating strategy identifies cells in a forward/side scatter plot (FCS-A and SSC-A) and then single cells are discriminated from doublets using SSC-W/SSC-H and FSC-W/FSC-H plots. Live cells are discriminated based on propidium iodide. Subpopulations are shown in red gates and identified as follows: HSCs (Lin-/CD34+/CD38−/CD45RA−/CD90+), MPPs (Lin−/CD34+/CD38−/CD45RA−/CD90−), LMPPs (Lin−, CD34+, CD38−, CD90−, CD45RA+), CMPs (Lin−/CD34+/CD38+/CD45RA−/CD123+), GMPs (Lin−/CD34+/CD38+/CD45RA+/CD123+), and MEPs (Lin−/CD34+/CD38+/CD45RA−/CD123−). HSCs: hematopoietic stem cells, MPPs: multipotent progenitors, LMPPs: lymphoid-primed multipotent progenitors, CMPs: common myeloid progenitors, GMPs: granulocyte-macrophage progenitors, MEPs: megakaryocyte-erythrocyte progenitors.
